Business
MIMEDX Comments on Prescience Point’s False and Misleading Statements
Cautions Shareholders Not to Let Prescience Point Unravel MIMEDX’s Transformation Urges Shareholders to Protect their Investments by Voting “FOR” Dr. Phyllis
About this update from Mimedx Group, Inc
[{"type":"text","content":"Cautions Shareholders Not to Let Prescience Point Unravel MIMEDX’s Transformation Urges Shareholders to Protect their Investments by Voting “FOR” Dr. Phyllis Gardner and James L. Bierman Highlights Prescience Point’s and Eiad Asbahi’s True Agenda MARIETTA, Ga., May 09, 2022 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today commented on Prescience Point Capital Management’s (“Prescience Point”) highly misleading press release on May 6, 2022. MIMEDX urges shareholders to vote “FOR” the Company’s highly qualified and independent directors – Dr. Phyllis Gardner and James L. Bierman – on the WHITE proxy card. MIMEDX Has the Right Board and Management Team to Continue Transforming the Company and Drive Significant Value Creation The MIMEDX Board and management team are made up of highly qualified executives and industry leaders who have transformed the Company after years of turmoil. The Board’s composition reflects significant input from shareholders and demonstrates a commitment to refreshment, increased diversity and subject-matter expertise, resulting in an entirely refreshed Board since June of 2019. The management team, led by Timothy R. Wright, has helped build an entirely new culture at the Company, rooted in ethics, integrity, and core values, which is methodically focused on strategic long-term execution. MIMEDX is confident in the steps we are taking to advance our strategy, and recently reported a third consecutive quarter of double-digit growth in our continuing portfolio of products. These results reflect the commercial team’s solid execution, and performance towards initiatives designed to achieve sustainable growth and enhance shareholder value. Led by Tim Wright, MIMEDX has also successfully accomplished a number of governance, operational and financial milestones that have been critical to restoring the Company’s credibility, integrity and reputation, improving business liquidity, and transforming the culture of the organization. A company’s integrity and credibility stem from exemplary leadership, and MIMEDX does not compromise on its core values and commitments. The two directors standing for re-election this year – Dr. Phyllis Gardner and Mr. James L. Bierman – both exemplify this commitment. Both are highly respected in the lif...